Exploring The Clever-1 Receptor Antibody as a Novel Mechanism to Target Macrophages in Cancer Treatment
Time: 10:30 am
day: Conference Day One
Details:
- Utilizing Bexmarilimab to target Clever-1, a novel mode-of-action to activate macrophage antigen presentation (ex vivo, spatial transcriptomics MATINS trial)
- Overcoming ICI resistance by targeting Clever-1
- Exploring Clever-1 as a new player in hematological malignancies through the BEXMAB trial
